

September 2017 APC Decisions

Medicine	Traffic light status	Indication	Other Information
Sucroferric oxyhydroxide (Velphoro®)	AMBER 1	Phosphate binder in patients with CKD on dialysis	Added to the existing Shared Care protocol as a second line non-calcium based phosphate binder. Only for patients who cannot tolerate sevelamer.
Omega-3-Acid Ethyl Esters	AMBER 3	Hypertriglyceridaemia	For the treatment of Hypertriglyceridaemia ONLY, in line with Hypertriglyceridaemia guideline. Prestylon® is preferred brand. Included in Nottinghamshire's Low Priority List for other indications- should not be prescribed on the NHS.
Glucodrate® rehydration sachets	AMBER 2	Rehydration for high output stoma	Second line for patients unable to tolerate St Marks Solution.
Colesevelam (Colestigel®, Sanofi)	GREY	Hypercholesterolaemia	Lack of supporting evidence
Chlortalidone (Alliance)	AMBER 2	Hypertension	For initiation by the hypertension clinic in patients who are unable to tolerate bendroflumethiazide or indapamide
Colestipol	GREY	Bile Acid Malabsorption	Lack of supporting evidence
Roflumilast (Daxas®)	AMBER 2	COPD	In line with NICE TA 461

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

Ratified at the meeting:

(Please note the final documents will be uploaded and available on the APC website within the next 2 weeks to allow for final editing)

- *Management of hyperlipidaemia and hypertriglyceridaemia (New)*
- *Ocular lubricants formulary (new)*
- *Sip feeds guidelines (update)*
- *Autoimmune hepatitis SCP (update)*
- *Phosphate binders for hyperphosphataemia SCP (Update)*
- *Testosterone prescribing information sheet (new)*
- *Antimicrobial Wound care guidelines (update)*

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Doxazosin MR - Reclassified as Amber 2 for specialists treating patients with difficult to treat hypertension and who are unable to tolerate IR doxazosin
- Fexofenadine - Reclassified as Green as price has decreased since original classification.
- Bovine Insulin - To be discontinued, reclassified as Grey
- Fluphenazine injection - To be discontinued, reclassified as Grey
- Zolmitriptan nasal spray - Added to formulary and highlight preference over sumatriptan nasal spray if patients experience vomiting

Horizon scanning

- Trimbaw® inhaler - Classified as Grey while a submission is awaited
- Feestyle Libre - Classified as Grey while a submission is awaited

Current work in development

- Review of the Triptan formulary chapter
- Melatonin for PD and elderly at risk of falls or suffering from dementia (New submission)
- Emollient Formulary (Review)
- Review of cost effective rectal foams

Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Hyperuricaemia (chronic) in gout - lesinurad	Guideline	April 2017 - delayed
Familial hypercholesterolaemia	Guideline	October 2017
Obesity, overweight with risk factors - naltrexone-bupropion	Technology Appraisal	October 2017
Sinusitis (acute): antimicrobial prescribing	Guideline	October 2017
Kidney transplantation immunosuppressive regimens	Technology Appraisal	October 2017
Asthma management	Guideline	October 2017
Asthma diagnosis and monitoring	Guideline	October 2017
Glaucoma: diagnosis and management	Guideline review	November 2017

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Lynne Kennel, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust